Dr Lewis describes the various investigational therapies that are underway with the potential to change the current treatment landscape of CIDP.
This is a video synopsis/summary of a panel discussion involving Richard Lewis, MD.
In the presented transcript, the speaker, Richard Lewis, discusses ongoing investigations into potential treatments for CIDP (chronic inflammatory demyelinating polyneuropathy). The focus is on a promising FcRn (neonatal Fc)inhibitor called efgartigimod, highlighted in a recent press release and poster presented at the American Academy of Neuro, Neuromuscular, and Electro Diagnostic Medicine. According to Richard Lewis, MD, this inhibitor demonstrated significant benefits for patients, potentially reducing circulating immunoglobulin G levels by 70% or more, thus impacting the pathophysiology of CIDP.
Dr Lewis expresses enthusiasm about efgartigimod, labeling it a groundbreaking treatment that, if approved, would be the first new CIDP therapy in over 30 years. The drug's subcutaneous administration, aided by hyaluronidase, adds to its appeal, especially considering its efficacy in a relatively short treatment period.
Additionally, Lewis discusses an early-phase study on a complement inhibitor, showing promise in refractory patients. Investigations into B-cell depletion for CIDP treatment also appear encouraging. Dr Lewis anticipates a significant expansion of treatment options for CIDP within the next 3 to 5 years. The challenge ahead lies in determining the most suitable treatment for individual patients, akin to complexities observed in myasthenia. Despite these challenges, Dr Lewis expresses optimism about the evolving landscape of CIDP treatment, with FcRn inhibition, B-cell depletion, and complement inhibition emerging as potential therapeutic avenues.
Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.